Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance II (MP62)1 Sep 2021MP62-14 THE INFLUENCE OF MAGNETIC RESONANCE IMAGING, GENOMIC CLASSIFIERS, AND POST-MAGNETIC RESONANCE IMAGING BIOPSY RESULTS ON SHARED-DECISION MAKING IN NEWLY DIAGNOSED FAVORABLE RISK PROSTATE CANCER PATIENTS Michael Wang, Ji Qi, Arvin George, James Montie, Michael Cher, Kevin Ginsburg, and for the Michigan Urological Surgery Improvement Collaborative Michael WangMichael Wang More articles by this author , Ji QiJi Qi More articles by this author , Arvin GeorgeArvin George More articles by this author , James MontieJames Montie More articles by this author , Michael CherMichael Cher More articles by this author , Kevin GinsburgKevin Ginsburg More articles by this author , and for the Michigan Urological Surgery Improvement Collaborative More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002102.14AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Magnetic resonance imaging (MRI), genomic classifiers (GC), and post-MRI biopsy (pMRI-Bx) have become increasingly integrated into the shared-decision making process for men with newly diagnosed prostate cancer deciding between definitive treatment and active surveillance (AS). We aimed to assess how these tests and combination of the results influenced initial management decisions. METHODS: We reviewed the Michigan Urological Surgery Improvement Collaborative registry for men with newly diagnosed favorable risk prostate cancer (FPRC: grade group (GG) 1 or low volume GG 2) from 06/2016 to 12/2019. All men included in this study obtained an MRI, with or without GC or pMRI-Bx. The primary outcome was the proportion of patients who selected AS and remained free of treatment one year after diagnosis. MRI, GC, pMRI Bx results were classified as reassuring (RA) vs non-RA according to predefined and previously published MUSIC criteria. Proportions were compared between groups using the Fisher’s exact test. RESULTS: Of the 1,394 men with FRPC who met inclusion criteria, 914 had an MRI alone, 140 had an MRI and GC, 295 had MRI and pMRI-Bx, and 45 had MRI, GC, and pMRI-Bx. Compared with men with RA MRI alone, more men with RA MRI/RA pMRI-Bx chose AS (95% vs. 84%, p=0.006) and fewer men with RA MRI/non-RA pMRI-Bx chose AS (35% vs. 84%, p<0.001, Figure 1). A similar proportion of men with RA MRI/RA GC and RA MRI/non-RA GC chose AS as men with RA-MRI alone (85% vs. 84, p=1.00 and 84% vs 84%, p=1.00, respectively). Compared with men with non-RA MRI alone, more men with non-RA MRI/RA pMRI-Bx chose AS (89% vs. 58%, p=0.001) and fewer men with non-RA MRI/non-RA pMRI-Bx chose AS (28% vs. 58%, p<0.001). Compared with nonRA MRI alone, a similar proportion of men with non-RA MRI/RA GC chose AS (64% vs. 58%, p=0.593) and fewer men with non-RA MRI/non-RA GC chose AS (28% vs. 58%, p=0.01). CONCLUSIONS: Post-MRI biopsy results strongly influenced the decision for treatment vs. AS compared with MRI results alone. In men with both GC and MRI, treatment decisions were mostly aligned with MRI results. These data suggest MRI and pMRI-Bx results are weighed more heavily by patients and providers compared with GC results. Source of Funding: Blue Cross Blue Shield of Michigan © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1097-e1098 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Wang More articles by this author Ji Qi More articles by this author Arvin George More articles by this author James Montie More articles by this author Michael Cher More articles by this author Kevin Ginsburg More articles by this author for the Michigan Urological Surgery Improvement Collaborative More articles by this author Expand All Advertisement Loading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call